Clinical Study for Xu-Ming-Tong-Mai Decoction in the treatment of Acute Ischemic Stroke
- Conditions
- Cerebral infarction
- Registration Number
- ITMCTR2000003280
- Lead Sponsor
- Chongqing Traditional Chinese Medicine Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- Not specified
1. All the patients were diagnosed as ischemic stroke by CT or MRI;
2. The NIHSS scores of patients ranged from 3 to 15(including 3 and 15);
3. Aged 40 to 80 years;
4. The patient's onset is less than 72 hours;
5. The trial was informed consent of the patient or the patient's family or their legal representative and signed the informed consent form.
1. Patients who have received or are about to undergo endovascular interventional therapy (including arterial thrombolysis, bridging, mechanical thrombectomy, angioplasty and stenting);
2. Tests confirmed patients with brain trauma, brain tumors, brain parasitosis, and other brain disorders, or with immune system disorders;
3. The score of the modified Rankin scale (Rankin scale) was more than 2;
4. Patients with malignant tumor, CACHEXIA, moderate or severe malnutrition (albumin < 25g / L, BMI <17);
5. Patients with severe hepatic and renal dysfunction (ALT or AST >80 U/L, The male Serum Creatinine >266 umol /L,The female Serum Creatinine >212 Umol/L);
6. Patients with other effects on limb function and limb function disorders affect the neurological examination;
7. Other diseases or mental disorders that the researchers believe may limit neurologic assessment or affect patient follow-up;
8. Pregnant or lactating women;
9. Patients undergoing clinical trials for other drugs;
10. Patients with contraindications to the drug therapy used in this study.
Study & Design
- Study Type
- Observational study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Serum S100B;neuron-specific enolase (NSE);
- Secondary Outcome Measures
Name Time Method